MARRON-CEMIPLIMAB-NEOADJUVANT
Regimen
- Experimental
- neoadjuvant cemiplimab 350 mg IV Q3W x2 cycles before resection, then 8 adjuvant cycles
Population
Resectable hepatocellular carcinoma. Single-arm phase 2 (Mount Sinai).
Key finding
4/20 (20%) achieved >70% pathological tumour necrosis with 2 cycles neoadjuvant cemiplimab; 15% radiographic PR. First published phase 2 of single-agent PD-1 neoadjuvant in resectable HCC.
Source: PMID 35065058